Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Arie Belldegrun Biography and Net Worth

Director of Allogene Therapeutics

Arie Belldegrun, MD, is the Executive Chairman and Co-Founder of Allogene. As a visionary entrepreneur, Arie founded Kite Pharma, a biopharmaceutical company engaged in the development of innovative cancer immunotherapies, where he served as Chairman, President and Chief Executive Officer until the acquisition of Kite by Gilead Sciences in October 2017. Arie has had a distinguished tenure in the life sciences, having been closely involved with the founding and advancement of several successful biopharmaceutical companies including Cougar Biotechnology and Agensys. Abiraterone, developed by Cougar, is a mainstay of therapy for patients with metastatic prostate cancer. He currently serves as Chairman of Two River Group, UroGen Pharma, Ltd. and Kronos Bio, and is a Co-Founder and Senior Managing Director of Vida Ventures. Arie is a Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, Arie was at the National Cancer Institute/NIH as a research fellow in surgical oncology and immunotherapy under Dr. Steven A. Rosenberg. He completed his MD at the Hebrew University Hadassah Medical School in Jerusalem, his post-graduate studies in Immunology at the Weizmann Institute of Science, and his residency in urologic surgery at Harvard Medical School. He has authored several books on oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy and cancer vaccines. He is certified by the American Board of Urology and is a member of the American Association of Genitourinary Surgeons.

What is Arie Belldegrun's net worth?: The estimated net worth of Arie Belldegrun is at least $3.81 million as of May 16th, 2024. Dr. Belldegrun owns 1,724,137 shares of Allogene Therapeutics stock worth more than $3,810,343 as of November 22nd. This net worth estimate does not reflect any other assets that Dr. Belldegrun may own. Additionally, Dr. Belldegrun receives an annual salary of $649,100.00 as Director at Allogene Therapeutics. Learn More about Arie Belldegrun's net worth.
How old is Arie Belldegrun?: Dr. Belldegrun is currently 75 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. Learn More on Arie Belldegrun's age.
What is Arie Belldegrun's salary?: As the Director of Allogene Therapeutics, Inc., Dr. Belldegrun earns $649,100.00 per year. There are 2 executives that earn more than Dr. Belldegrun. The highest earning executive at Allogene Therapeutics is Dr. David D. Chang M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $994,600.00 per year. Learn More on Arie Belldegrun's salary.
How do I contact Arie Belldegrun?: The corporate mailing address for Dr. Belldegrun and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Arie Belldegrun's contact information.
Has Arie Belldegrun been buying or selling shares of Allogene Therapeutics?: Arie Belldegrun has not been actively trading shares of Allogene Therapeutics during the last quarter. Most recently, on Thursday, May 16th, Arie Belldegrun bought 1,724,137 shares of Allogene Therapeutics stock. The stock was acquired at an average cost of $2.90 per share, with a total value of $4,999,997.30. Following the completion of the transaction, the director now directly owns 1,724,137 shares of the company's stock, valued at $4,999,997.30. Learn More on Arie Belldegrun's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), and Owen Witte (Director). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, Allogene Therapeutics insiders bought shares 2 times. They purchased a total of 1,724,327 shares worth more than $5,000,681.30. During the last year, insiders at the sold shares 2 times. They sold a total of 29,840 shares worth more than $76,536.00. The most recent insider tranaction occured on May, 30th when Director Franz B Humer sold 11,200 shares worth more than $26,208.00. Insiders at Allogene Therapeutics own 24.3% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 5/30/2024.

Arie Belldegrun Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2024	Buy	1,724,137	$2.90	$4,999,997.30	1,724,137
1/12/2022	Buy	155,039	$12.60	$1,953,491.40
6/4/2020	Buy	146,382	$43.00	$6,294,426.00
10/15/2018	Buy	35,000	$18.00	$630,000.00

Arie Belldegrun Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.21

$2.09

$2.23

50 Day Range

MA: $2.69

$2.05

$3.22

2 Week Range

Now: $2.21

$1.99

$5.78

Volume

1,416,891 shs

Average Volume

2,660,311 shs

Market Capitalization

$463.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.84

Trump won. Buy this coin now.

From Weiss Ratings | Ad

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

Arie Belldegrun Biography and Net Worth

What is Arie Belldegrun's net worth?

How old is Arie Belldegrun?

What is Arie Belldegrun's salary?

How do I contact Arie Belldegrun?

Has Arie Belldegrun been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?